pk 11195 has been researched along with Chronic Disease in 10 studies
PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rats were subjected to permanent middle cerebral artery occlusion (pMCAO) by the macrosphere model and monitored by MRI and PET for 28 or 56 days, followed by immunohistochemical endpoint analysis." | 1.42 | In vivo analysis of neuroinflammation in the late chronic phase after experimental stroke. ( Backes, H; Fink, GR; Graf, R; Hoehn, M; Neumaier, B; Rueger, MA; Schroeter, M; Walberer, M; Walter, HL; Wiedermann, D, 2015) |
| "Ferulic acid is a natural compound that expresses antioxidant and anti-inflammatory activities." | 1.32 | Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid. ( Gasparini, L; Hauss-Wegrzyniak, B; Maucci, R; McGann-Gramling, K; Ongini, E; Ronchetti, D; Rosi, S; Wenk, GL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaunzner, UW | 1 |
| Kang, Y | 1 |
| Zhang, S | 1 |
| Morris, E | 1 |
| Yao, Y | 1 |
| Pandya, S | 1 |
| Hurtado Rua, SM | 1 |
| Park, C | 1 |
| Gillen, KM | 1 |
| Nguyen, TD | 1 |
| Wang, Y | 1 |
| Pitt, D | 1 |
| Gauthier, SA | 1 |
| Bogdanović, RM | 1 |
| Syvänen, S | 1 |
| Michler, C | 1 |
| Russmann, V | 1 |
| Eriksson, J | 1 |
| Windhorst, AD | 1 |
| Lammertsma, AA | 1 |
| de Lange, EC | 1 |
| Voskuyl, RA | 1 |
| Potschka, H | 1 |
| Walberer, M | 2 |
| Jantzen, SU | 1 |
| Backes, H | 2 |
| Rueger, MA | 2 |
| Keuters, MH | 1 |
| Neumaier, B | 2 |
| Hoehn, M | 2 |
| Fink, GR | 2 |
| Graf, R | 2 |
| Schroeter, M | 2 |
| Walter, HL | 1 |
| Wiedermann, D | 1 |
| Hunter, HJ | 1 |
| Hinz, R | 1 |
| Gerhard, A | 1 |
| Talbot, PS | 1 |
| Su, Z | 1 |
| Holland, G | 1 |
| Hopkins, SJ | 1 |
| Griffiths, CE | 1 |
| Kleyn, CE | 1 |
| Garvey, LJ | 1 |
| Pavese, N | 1 |
| Ramlackhansingh, A | 1 |
| Thomson, E | 1 |
| Allsop, JM | 1 |
| Politis, M | 1 |
| Kulasegaram, R | 1 |
| Main, J | 1 |
| Brooks, DJ | 1 |
| Taylor-Robinson, SD | 1 |
| Winston, A | 1 |
| Tegler, G | 1 |
| Sörensen, J | 1 |
| Ericson, K | 1 |
| Björck, M | 1 |
| Wanhainen, A | 1 |
| Wenk, GL | 1 |
| McGann-Gramling, K | 1 |
| Hauss-Wegrzyniak, B | 1 |
| Ronchetti, D | 1 |
| Maucci, R | 1 |
| Rosi, S | 1 |
| Gasparini, L | 1 |
| Ongini, E | 1 |
| Kurumaji, A | 1 |
| Wakai, T | 1 |
| Toru, M | 1 |
| Perney, P | 1 |
| Butterworth, RF | 1 |
| Mousseau, DD | 1 |
| Lavoie, J | 1 |
| Fabbro-Peray, P | 1 |
| Blanc, F | 1 |
| Layrargues, GP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Subcutaneous Cladribine for Nonrelapsing, Secondary Progressive Multiple Sclerosis (CLASP-MS): a Randomized, Placebo-controlled, Double-blind, Phase 2 Study.[NCT05961644] | Phase 2/Phase 3 | 188 participants (Anticipated) | Interventional | 2022-10-03 | Recruiting | ||
| Evaluation of the Degree of Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Positron Emission Tomography With Amyloid Markers (PET-CT 18F-Florbetaben) and Comparison With MRI Findings[NCT05783934] | 20 participants (Anticipated) | Interventional | 2021-07-27 | Recruiting | |||
| A Prospective Case-control Study to Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-infection - a PET Study[NCT00959166] | 81 participants (Actual) | Interventional | 2009-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Association of 11C-labelled PK11195 uptake using PET with acute HCV and HIV infection by PK11195 PET ligand binding. The ligand PK11195 is selective for the peripheral benzodiazepine binding site and exhibits minimal binding in normal brain. In brain lesions, however, there is a massive increase in binding. (NCT00959166)
Timeframe: 30 days
| Intervention | binding potential ratio (Mean) |
|---|---|
| HIV/Acute HCV Coinfection | 0.18 |
| HIV Mono | 0.22 |
"Association between patient characteristics and 11C-labelled PK11195 uptake using PET, CNS metabolite ratios.~By quantifying the surrogate markers of N-acetylaspartate (NAA), creatine (Cr) offers insight into the neuronal integrity, cell membrane synthesis and turnover, macrophage infiltration, inflammation status, and levels of microglial activation and gliosis within the sampled CNS tissue." (NCT00959166)
Timeframe: 30 days
| Intervention | ratio (Mean) |
|---|---|
| HIV/Acute HCV Coinfection | 1.42 |
| HIV Mono | 1.35 |
10 other studies available for pk 11195 and Chronic Disease
| Article | Year |
|---|---|
Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Brain; Carbon Radioisotopes; C | 2019 |
Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Brain; Carbon Radioisotopes; C | 2019 |
Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Brain; Carbon Radioisotopes; C | 2019 |
Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Brain; Carbon Radioisotopes; C | 2019 |
(R)-[11C]PK11195 brain uptake as a biomarker of inflammation and antiepileptic drug resistance: evaluation in a rat epilepsy model.
Topics: Animals; Anticonvulsants; Brain; Carbon Radioisotopes; Carrier Proteins; Chronic Disease; Disease Mo | 2014 |
In-vivo detection of inflammation and neurodegeneration in the chronic phase after permanent embolic stroke in rats.
Topics: Amyloid; Animals; Brain; Carbon Radioisotopes; Chronic Disease; Disease Models, Animal; Immunohistoc | 2014 |
In vivo analysis of neuroinflammation in the late chronic phase after experimental stroke.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Brain; Brain Ischemia; Calcium-Bin | 2015 |
Brain inflammation and psoriasis: a [
Topics: Adolescent; Adult; Carbon Radioisotopes; Chronic Disease; Encephalitis; Female; Humans; Isoquinoline | 2016 |
Acute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation.
Topics: Acute Disease; Adult; Biological Transport; Carbon Radioisotopes; Case-Control Studies; Cerebral Cor | 2012 |
4D-PET/CT with [(11)C]-PK11195 and [(11)C]-(D)-deprenyl does not identify the chronic inflammation in asymptomatic abdominal aortic aneurysms.
Topics: Aged; Aortic Aneurysm, Abdominal; Aortitis; Asymptomatic Diseases; Biopsy; Carbon Radioisotopes; Chr | 2013 |
Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents; Antioxidants; Butanes; Chronic Disease; Coumar | 2004 |
Decreases in peripheral-type benzodiazepine receptors in postmortem brains of chronic schizophrenics.
Topics: Adult; Aged; Brain; Brain Chemistry; Chronic Disease; Female; Humans; Isoquinolines; Kinetics; Male; | 1997 |
Plasma and CSF benzodiazepine receptor ligand concentrations in cirrhotic patients with hepatic encephalopathy: relationship to severity of encephalopathy and to pharmaceutical benzodiazepine intake.
Topics: Animals; Benzodiazepines; Binding, Competitive; Cell Fractionation; Cerebellum; Chronic Disease; Clo | 1998 |